Literature DB >> 2095348

Ivermectin binds avidly to plasma proteins.

U Klotz1, J E Ogbuokiri, P O Okonkwo.   

Abstract

Human pharmacokinetic data on the new anti-parasitic agent, ivermectin, are scanty. For the evaluation of its disposition a specific HPLC assay with sensitive fluorescence detection was developed. Applying equilibrium dialysis, plasma protein binding of ivermectin was measured in five healthy individuals and it averaged 93.2 +/- 4.4% (SD). Such strong binding should be taken into consideration, especially in patients with malnutrition or with diseases in which a decrease in plasma proteins and consequently a higher free fraction of ivermectin could be expected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095348     DOI: 10.1007/bf00316107

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution.

Authors:  G Edwards; A Dingsdale; N Helsby; M L Orme; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis.

Authors:  K Awadzi; K Y Dadzie; H Shulz-Key; D R Haddock; H M Gilles; M A Aziz
Journal:  Ann Trop Med Parasitol       Date:  1985-02
  2 in total
  9 in total

Review 1.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

Review 2.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Ivermectin levels in human breastmilk.

Authors:  J E Ogbuokiri; B C Ozumba; P O Okonkwo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Ivermectin levels in human breast milk.

Authors:  J E Ogbuokiri; B C Ozumba; P O Okonkwo
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.

Authors:  Laura Ceballos; Laura Moreno; Luis Alvarez; Laura Shaw; Ian Fairweather; Carlos Lanusse
Journal:  BMC Vet Res       Date:  2010-02-03       Impact factor: 2.741

Review 6.  Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.

Authors:  Slobodan P Rendic
Journal:  Arch Toxicol       Date:  2021-03-15       Impact factor: 5.153

Review 7.  Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?

Authors:  Leon M T Dicks; Shelly M Deane; Matthew J Grobbelaar
Journal:  Probiotics Antimicrob Proteins       Date:  2022-02-25       Impact factor: 5.265

Review 8.  The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review.

Authors:  Asiya Kamber Zaidi; Puya Dehgani-Mobaraki
Journal:  J Antibiot (Tokyo)       Date:  2021-12-21       Impact factor: 2.649

9.  The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.

Authors:  Virginia D Schmith; Jie Jessie Zhou; Lauren R L Lohmer
Journal:  Clin Pharmacol Ther       Date:  2020-06-07       Impact factor: 6.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.